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Background:
• Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 2 to 3% of all adult malignancies.1 Up to 30% of patients with renal-cell carcinoma present with metastatic disease. 2 The average overall survival (OS) without treatment ranges from 6 to 12 months. 3 In Ecuador, according Globocan Statistics, 269 patients were estimated in 2008 with mRCC 4, 5 .
Objective:
• The aim of the study was to estimate the annual economic budget impact of the introduction of Axitinib as a therapy for metastatic renal cell carcinoma (mRCC) in the budget of the Ministry of Public Healthcare in Ecuador to predict the financial consequences of introducing Axitinib as a second line treatment in Ecuador.
Methods:
• Using a budget Impact analysis model, we estimated the incremental impact in the Ministry of Public Healthcare budget in Ecuador with the introduction of Axitinib as treatment for mRCC in whom have failed the first line treatment. The model is an incidence based model. The number of metastatic RCC patients is determined by the incidence of RCC, the proportions of disease that are diagnosed as metastatic and non-metastatic (localized and regional), and the annual percentage of non-metastatic patients who progress to metastatic disease. Then this population will only be eligible for Axitinib if they have received a first line of treatment and are eligible to continue another line of treatment. Eligible patients are allocated to different comparator medications based on the estimated market share of therapies in the reference years. Once Axitinib is introduced, Axitinib market share increases each year and subsequently reduces market share of comparator therapies. Corresponding treatment costs (drug and toxicity costs) are calculated based on the market share mix, incidence of toxicities and the resource use data of toxicity management, which is based on Ecuatorian KOL input. The model structure is shown in Figure 1 .
Results:
• Based on the incidence of RCC and the Ecuador population, we calculated 269 incident cases of mRCC, 211 incident cases diagnosed with metastatic disease and 58 who will progress to metastatic disease, 97 patients received a first line treatment of whom 40.91% (40 patients) needed a 2nd line treatment.
• Along a 3 year follow-up in the scenario were Axitinib was added, the estimated cost was $5,810,416.84 USD, with an incremental change of $26,098.99 USD and an incremental cost for the population with access to the National Healthcare System of $0.00010 USD p/month (Table 4, Figure 2 ).
Conclusion:
• The addition of Axitinib as a second line treatment for mRCC had a minimal impact on the budget designated to the Ministry of Public Healthcare in Ecuador, and since it has an A1 recommendation level, it will represent an improvement in the mRCC treatment options.
• Compared with the higher costs therapies currently used in Ecuador for the treatment of mRCC, Axitinib may offer savings as a replacing therapy. • The estimated patients in second line of treatment were calculated as shown in Table 1 : Table 1 . Epidemiology Data Table 3 . Market Share and Axitinib Uptake Assumptions for the Second-line Treatment of mRCC Table 3 . Total Costs Over 3 Years of Treatment. Figure 2 . Total Budget Over 3 Years Treatment.
• The comparative used drugs were Sorafenib, Everolimus, Sunitinib, Pazopanib and Bevacizumab + IFNa.
• The costs information was obtained from public sources10 and the model was built in Microsoft Excel 2007.
• Data inputs included mRCC treatment cost and market shares are described in Tables 2 -3 . 
